Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023: One-Stop Source for Providing Real-Deal Information on Hundreds of Transactions
The report titled "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" has been released by ResearchAndMarkets.com. This comprehensive report offers insights into partnering deals in the pharmaceutical and biotechnology sectors, including details on technology licensed, royalty rates, license fees, and other payments. It covers all disclosed deals since 2010, providing essential data for prospective dealmakers. Key chapters analyze royalty rate trends, the structure of royalty clauses, and leading companies in the field. The report aims to equip readers with the necessary tools for effective negotiations and due diligence in licensing agreements.
- Provides a comprehensive listing of all partnering deals with disclosed royalty rates since 2010.
- Includes real-life case studies that illustrate the structure of royalty clauses.
- Offers access to actual contract documents for detailed insights into deal terms.
- Introduces key benefits for understanding royalty rate trends and deal structures.
- None.
DUBLIN ,
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2023.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca,
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Key benefits
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 provides the reader with the following key benefits:
- In-depth understanding of royalty rate partnering deal trends since 2010
- Analysis of the structure of royalty clauses with real life case studies
- Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
- Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
- Insight into the royalty terms included in a licensing agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 includes:
- Trends in royalty rates in the biopharma industry since 2010
- Analysis of the structure of royalty clauses with real life case studies
- Comprehensive listing of licensing deals which disclose royalty rates since 2010
- Access to licensing contract documents which disclose royalty rates
- The leading licensing deals by royalty rate value since 2010
- Most active royalty rate disclosures since 2010
In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 available deals and contracts are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023 report provides comprehensive access to available contract documents for licensing deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise royalty rates granted?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
- 3D Medicines
- Abbott Laboratories
- Abbvie
- Ablynx
- Abraxis BioScience
Acceleron Pharma - Acerus
- Actavis (acquired by
Watson ) - Active Biomaterials
- Acura Pharmaceuticals
- Adamis Pharmaceuticals
Adaptimmune Adeona Pharmaceuticals - Adlai Nortye
- Aduro BioTech
- Advanced Dosage Forms
- Advaxis
- Advirna
- Aegerion Pharmaceutical
- AEterna Zentaris
- Afritex Medical Products
- Agenus Bio
- Agios Pharmaceuticals
- AIT Therapeutics
Akcea Therapeutics - Akebia Therapeutics
- Alchemia
- Alder Biopharmaceuticals
- Alector
- Alexion Pharmaceuticals
Alexza Pharmaceuticals Alfasigma Alfa Wassermann - Allergan
- Allergan (name changed from Actavis)
- Almirall
- Alnylam Pharmaceuticals
- Alternavida
Altman Enterprises - AltrazealTrading
- Amarantus BioSciences
American Type Culture Collection (ATCC)- Amgen
Amherst Pharmaceuticals - Amorfix Life Sciences
- Ampio Pharmaceuticals
Amylin Pharmaceuticals - Amyris
- AnaBios
- AnGes MG
- AnnaMed
- Antibe Therapeutics
- Antigen Express
- Apricus Biosciences
- Aquestive Therapeutics
Aradigm Aratana Therapeutics Arch Pharmalabs - Ardelyx
Arena Pharmaceuticals - Assembly Biosciences
- Astellas Pharma
Astellas Pharma Europe Asterias Biotherapeutics - AstraZeneca
- Athenex
- Atossa Genetics
Audeo Oncology - Aurigene Discovery Technologies
Authentic Brands Group - AVEO Oncology
- Avita Medical
- Avivagen
- Axovant Sciences
- Aytu BioScience
Azaya Therapeutics Azure Biotech - Baker Brothers Investments
- BASF
- Baxter International
Bayer Healthcare - Bayer Innovation
Baylor Research Institute - Belgian Volition
- Bellerophon Therapeutics
- Benitec Biopharma
Besins Healthcare Beth Israel Deaconess Medical Center - BIND Biosciences
- BioCorRx
- BioCryst Pharmaceuticals
- Bioeq IP
- Biogen
- BioGene Technology
- BioInvent
- BiolineRX
- BioMarin Pharmaceutical
- BioNovion
- BioNTech
- Biopharmex
- BiopharmX
- BioPorto
Bioprocess Capital Ventures - BioProspect
Biostem US Biotech Investment Biotechnology Value Fund - BioTime Acquisition
- Bioton
Biovail BioZone Laboratories - BioZone Pharmaceuticals
- Bluebird Bio
- BMV Medica
Boehringer Ingelheim Braeburn Pharmaceuticals - BrainStorm Cell Therapeutics
Breathtec BioMedical Bristol-Myers Squibb Caleco Pharma - Calico
- Can-Fite BioPharma
Cancer Prevention Pharmaceuticals CanniMed Therapeutics - Canntab Therapeutics
Cannus Partners Cantex Pharmaceuticals Cardigant Medical - Cardium Therapeutics
CareFusion Cary Pharmaceuticals Castle Creek Pharmaceuticals - Catalent
- CB2 Therapeutics
Celdara Medical - Celgene
Cell Cure Neurosciences - Cel Sci
- Celyad
- Cereal Ingredients
- Cerus
- cGreen
- Chi-Med
Chiesi Farmaceutici - Chimerix
- Chong Kun Dang
- Chongqing Jingdong Pharmaceutical
- Cimtech
- Cipher Pharmaceuticals
- Cipla
- Circassia
- Clal Biotech
Clalit Health Services Clemson University - Cleveland BioLabs
Clinigen - CMIC
- CNS Pharmaceuticals
- Cocrystal Pharma
Coeptis Pharmaceuticals Cohen-McNiece Foundation - Coherus Biosciences
Colby Pharmaceuticals Columbia Laboratories Columbia University - Common Sense
- Concile
- ContraFect
- Coronado Biosciences
- CRISPR Therapeutics
Crucell - CTT Pharmaceutical
- Cumberland Pharmaceuticals
- Cures Within Reach
CureTech - Curis
Currax Pharmaceuticals CURx Pharmaceuticals Cutanea Life Sciences - Cypress Bioscience
- Cytodyn
- Cytori Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
Dana-Farber Cancer Institute - Dance Biopharm
- DAS Therapeutics
- Defiante Farmaceutica
- Denali Therapeutics
- Derma Sciences
- Dermin
- Dianomi Therapeutics
- Dicerna Pharmaceuticals
- DNA Biomedical Solutions
Dr. Falk Pharma - Dr. Reddy's Laboratories
Drugs for Neglected Diseases Initiative DS Healthcare Duke University Dyax - Eagle Pharmaceuticals
- Eagle Pharmaceuticals (US)
- Easton Pharmaceuticals
- Echo Therapeutics
- Ecology Coatings
Eddingpharm - Egalet
- Eisai
- Elencee
- Eli Lilly
- Elite Pharmaceuticals
- Emergent BioSolutions
Emory University Endocyte Endo Pharmaceuticals - Enochian Biosciences
- Entera Bio
- Entest BioMedical
- EnWave
Epizyme Epocal - Esperion Therapeutics
Eternity Healthcare - Eureka Genomics
- EUSA Pharma
- Evolva
- Exact Sciences
- Exelixis
- Eyevance
Fairview Health System FasTrack Pharmaceuticals Fibrocell Science - Fibrogen
Forest Laboratories - Fosun Pharmaceutical
Fresenius Kabi Pharmaceuticals - FSD Pharma
- FusionVax
- Galapagos
- Galmed Pharmaceuticals
Genentech Generex Biotechnology - Genevant Sciences
- Genmab
- Gentium
Genzyme - Geron
- Gilead Sciences
- GlaxoSmithKline
Glenmark Generics Inc USA - Glenmark Pharmaceuticals
Goldfinch Bio Government of Israel - Gravocore
- Grifols
- GT Biopharma
- Hail First Pharma
- Hainan Sihuan Pharmaceutical
- Halo Labs
- Halozyme Therapeutics
Hansen Medical Health Canada - Health Discovery
- Heat Biologics
- Hefei Life Science
- Hefei Tianhui Incubation of Technologies
- HemoCleanse
- Hemogenyx
- HemPup
HIBM Research Group - Hikma Pharmaceuticals
Hoffmann La Roche Hollister Biosciences - Hookipa Pharma
- Horizon Pharma Inc
- HyperGenomics
Icahn School of Medicine at Mount Sinai - Ice + Jam
- IDC-GP Pharm
- Idera Pharmaceuticals
- Idorsia
- iMetabolic
Biopharma - Immugenyx
- Immunomic
- Immunovative Therapies
Impax Laboratories Imprimis Pharmaceuticals - iNAP
- Incuron
- Incyte
- Infinity Pharmaceuticals
- Inhibitor Therapeutics
- Innate Pharma
- Innocoll
- Innovation Pharmaceuticals
Innovus Pharmaceuticals INO Therapeutics Inspiration Biopharmaceuticals Instrumentation Laboratory - IntelGenx
IntelliCell BioSciences - Intellikine
Internet Marketing Consortium Intrexon - Intuitive Surgical
- Invekra
- Inverness Medical Innovations
- Ionis Pharmaceuticals
- Ipsen
- Ironwood Pharmaceuticals
Israeli National Authority for Technological Innovation - Jaguar Health
Janssen Biotech Janssen Pharmaceuticals - Jazz Pharmaceuticals
- JFC Technologies
- Jiangsu Alphamab
Jiangsu Lianhuan Pharmaceuticals - Jiangsu NHWA Pharmaceutical
John Morley Foods Juniper Pharmaceuticals - K2M
Kadmon Pharmaceuticals KaloBios Pharmaceuticals - KemPharm
Kensey Nash Kieran Murphy - Kinetic Concepts
- Kiniksa Pharmaceuticals
- Kitov
- Klaria
Knighton Foods - Knight Therapeutics
- Kodiak Sciences
- Kraig Biocraft Laboratories
KVK-Tech - Kwang Dong Pharmaceutical
- Kyowa Hakko Kirin
- Laboratories Acbel
Legend Biotech - Level Brands
LFB Biotechnologies - Lifestyle Delivery Systems
- Ligand Pharmaceuticals
- Lubrizol
- Lumenis
- Lundbeck
- MabCure
- Macrogenics
- Magenta Therapeutics
- MainPointe
- Mallinckrodt Pharmaceuticals
- Marvanal
Marv Enterprises Massachusetts General Hospital - Mayne Pharma
McComb Foundation McEwen Centre for Regenerative Medicine - Meda
- Medica
- Medica Avante
- Medical Technologies Innovation Asia
Medicines Patent Pool Foundation - MediGene
- MedImmune
- Medison Pharma
Medivation - Medivir
Medovex - Melmed
- Memory Dx
- Merck and Co
- Merck KGaA
Merck Serono - Merus
Micromet - Mikah Pharma
- Millennium
- Mimi's Rock
- Ministry of Health
- Labor and Welfare
- Miraculins
- Moderna Therapeutics
- Moleculin Biotech
Mologen - Morgan Stanley
- MorphoSys
- MultiCell Immunotherapeutics
Munich Leukemia Laboratory - NantCell
- Nantong Jinghua Pharmaceutical
NantWorks Napo Pharmaceuticals - Natac Biotech
Natco Pharmaceuticals - National Green Biomed
- Nektar Therapeutics
- Neogenomics
- Nephrogenex
- Nephros
- Neurocrine Biosciences
NeuroSigma - NeuroVive Pharmaceutical
NeuroVive Pharmaceutical Asia - NewLeaf Brands
- Newsoara Biopharma
New York University - NexMed
- Nextleaf Solutions
- Nexvet
- NGM Biopharmaceuticals
- Nicox
- Nordic Bioscience
- Norgine
Notable Labs Novadaq Technologies - NovaDel Pharma
- Novan
- Novan Therapeutics
- Novartis
- Novartis Vaccines and Diagnostics
- Novocure
Novus Biologicals - Nucorion
- Nurix
- Nutech Medical
- NutraOrigin
- NXTGEN
- Nymox Pharmaceutical
Oberland Capital - Oculus Innovative Sciences
- Ocumension Therapeutics
- Omeros
- Oncologie
- Oncolytics Biotech
OncoMed Pharmaceuticals - Onegevity
- One Way Liver Genomics (OWL)
Onyx Pharmaceuticals - Opexa Therapeutics
- OptiBiotix
- OptiNose
- Oragenics
- Oramed Pharmaceuticals
- Orexigen Therapeutics
- Organovo
- Orgenesis
- Orion
Orox Pharmaceuticals OrthoCyte - Otsuka
- OvaMed
- Oxford BioMedica
- Oxis Biotech
- Oxygen Biotherapeutics
- OxySure Systems
- Pan-Provincial Vaccine Enterprise
Parnell Pharmaceutical Holdings - Par Pharmaceutical
- PDL BioPharma
Penwest Pharmaceuticals Pernix Therapeutics Perugia University - Pfizer
Pharmacyclics - PharmaMar
- PharmaNova
- Pharmastrip
- Phosphagenics
- Phusion Laboratoies
- Phyto Nutricare
- Pieris
Pipex Pharmaceuticals - Plandai Biotechnology
- Pluristem Therapeutics
- Portola Pharmaceuticals
- Poseida Therapeutics
Pozen PreMD - Premier Biomedical
Professional Compounding Centers of America Progenics Pharmaceuticals - Prometic Life Sciences
- ProQR Therapeutics
- Prosidion
- Protalix BioTherapeutics
- Proteonomix
Prothena Biosciences - ProtoKinetix
- Pulmatrix
- Puma Biotechnology
QRxPharma - Quick Med Technologies
Quigley Corporation - Reata Pharmaceuticals
- Recordati
- Recro Pharma
RedHill Biopharma - Reedy Creek Investments
- RegenaStem
- Regeneron Pharmaceuticals
- Relmada Therapeutics
- ReNeuron
- Resarci Therapeutics
- Retrophin
- rEVO Biologics
- Revolution Medicines
- Rigel Pharmaceuticals
- RNL Bio
- Roche
Rockefeller University - Roivant Sciences
- Royalty Pharma
- RST Biomedikal Sanayi
- Ruthigen
RXi Pharmaceuticals - S2 Therapeutics
- SACCO
- Sage Therapeutics
Salix Pharmaceuticals Sam Amer - Sandoz
- Sanofi
Sanofi-Aventis Sanofi-Pasteur Santarus - Santen Pharmaceutical
- SA Pathology
- Sarepta Therapeutics
- Seattle Genetics
- Seelos Therapeutics
- Senetek
- Sermonix Pharmaceutical
Sheba Medical Center Shenzhen BioScien Pharmaceuticals - Shield Therapeutics
- Shionogi
- Shire Pharmaceuticals
- Shore Therapeutics
- Sigma-Tau
Sinclair Pharmaceuticals - Sinobiopharma
- Sinopharm
- Skinvera
Skyline Diagnostics - Solarvest BioEnergy
Soliance - Soligenix
- Sorrento Therapeutics
Spectranetics - Spencer Pharmaceutical
Spinal USA St. Jude Children's Research Hospital - STADA Arzneimittel
- Stealth Therapeutics
- Stellar Biotechnologies
- St Jude Medical
Strongbridge Biopharma Sucampo AG - Sunesis Pharmaceuticals
SuperNova Diagnostics - Swedish Orphan Biovitrum
- Symbollon
- Synergy Strips
- Syntopix
- Tactical Relief
- Taiba
- Takeda Pharmaceutical
- Tango Therapeutics
- Target Group
- Tauriga Sciences
TB Alliance Technion Research and Development Foundation - Tetra Bio-Pharma
- TetraLogic Pharmaceuticals
- Teva Pharmaceutical Industries
Texas A&M University - Therakine
- Theravance
- Theravance Biopharma
- The Regents of the
University of California Thorne Research Threshold Pharmaceuticals - TiGenix
- Tilray
- Titterington Veterinary Services
- Tiziana Life Sciences
- TONIX Pharmaceuticals
- Torii Pharmaceutical
- TRACON Pharmaceuticals
- Tramorgan
- Transgene
- Trellis Bioscience
- Trevena
Trimedyne - Trimeris
- TrovaGene
- TTFactor
Turnstone Biologics Tyme Technologies Ultragenyx Pharmaceuticals - Uluru
Unigene Laboratories - UniQure
Universal Cells University Health Network University of Alberta University of California University of Central Florida Research Foundation University of Colorado University of Florida Research Foundation University of Geneva University of Missouri University of Notre of DameUniversity of Pennsylvania University of Western Sydney University of Zurich - UOP
- Uppsalagruppen Medical
- Upstream Peripheral Technologies
- UroGen Pharma
Valeant Pharmaceuticals - ValiPharma
- Valor Biotherapeutics
Vanderbilt University - Vasomune Therapeutics
Vaxent VBL Therapeutics (dba)- Veloxis Pharmaceuticals
- Veracyte
Verenium - VeroScience
- Vertex Pharmaceuticals
- Vida Concepts
ViiV Healthcare - Virbac
Viropharma - VistaGen Therapeutics
- Vividion Therapeutics
- VolitionRX
- Voyager Therapeutics
Vyera Pharmaceuticals Vyrix Pharmaceuticals Watson Pharmaceuticals - WAVE Life Sciences
Wisconsin Alumni Research Foundation - World Class Extractions
- WPD Pharmaceuticals
- Xbrane Bioscience
- Xencor
- XTL Biopharmaceuticals
Xynomic Pharmaceuticals Yale University Yeda Research and Development Company Yeugnam University - ZAI Laboratory
- Zalicus
Zenitech - Zenith Epigenetics
- Ziopharm Oncology
- ZS Pharma
For more information about this report visit https://www.researchandmarkets.com/r/4j3g2b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For
For GMT Office Hours Call +353-1-416-8900
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:SOURCE
FAQ
What is the main focus of the Global Royalty Rate Trends report?
How can the report assist dealmakers in the pharma and biotech industries?
What companies are highlighted in the Global Royalty Rate Trends report?
What time period does the report cover regarding royalty rates?
What insights can be gained about royalty clauses from the report?
